Abstract | OBJECTIVES: Successful therapy of carbapenem-resistant Acinetobacter baumannii strains has been reported with colistin, but recently we argued against its use as monotherapy because of the poor results obtained in a mouse pneumonia model. Our aim was to identify antibiotic combinations that were valid therapeutic alternatives in the same model. METHODS: RESULTS: In infections caused by strain D, lung bacterial counts (log(10) cfu/g, mean +/- s.d.) were: controls (10.86+/-0.25), imipenem (5.99+/-0.59, P < 0.05 versus controls), and colistin (10.43 +/- 1.09); imipenem + tobramycin was the most active combination (5.46+/-0.62, P < 0.05 versus controls). In infections caused by strain E, results were: controls (10.82+/-0.33), rifampicin (5.62+/-0.26, P < 0.05 versus controls), colistin (8.38+/-1.22, P < 0.05 versus controls), and imipenem (11.01+/-0.2); rifampicin + imipenem (3.79+/-0.99) and rifampicin + tobramycin (3.96+/-0.30) were the most active combinations (P < 0.05); results with rifampicin + colistin (5.59+/-1.17) were similar to those with rifampicin alone. CONCLUSIONS:
|
Authors | Abelardo Montero, Javier Ariza, Xavier Corbella, Alejandro Doménech, Carmen Cabellos, Josefina Ayats, Fe Tubau, Carmen Borraz, Francesc Gudiol |
Journal | The Journal of antimicrobial chemotherapy
(J Antimicrob Chemother)
Vol. 54
Issue 6
Pg. 1085-91
(Dec 2004)
ISSN: 0305-7453 [Print] England |
PMID | 15546972
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Anti-Bacterial Agents
- Carbapenems
- beta-Lactams
- Rifampin
- Tobramycin
- Colistin
|
Topics |
- Acinetobacter Infections
(drug therapy, microbiology)
- Acinetobacter baumannii
(drug effects)
- Animals
- Anti-Bacterial Agents
(pharmacology, therapeutic use)
- Carbapenems
(pharmacology)
- Colistin
(pharmacology, therapeutic use)
- Disease Models, Animal
- Drug Resistance, Bacterial
- Drug Therapy, Combination
(pharmacology, therapeutic use)
- Female
- Humans
- Mice
- Mice, Inbred C57BL
- Microbial Sensitivity Tests
- Pneumonia, Bacterial
(drug therapy, microbiology)
- Rifampin
(pharmacology, therapeutic use)
- Tobramycin
(pharmacology, therapeutic use)
- beta-Lactams
(pharmacology, therapeutic use)
|